CSIMarket
 


Deciphera Pharmaceuticals Inc   (DCPH)
Other Ticker:  
 
 

DCPH's Revenue Growth by Quarter and Year

Deciphera Pharmaceuticals Inc 's Revenue results by quarter and year




DCPH Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 48.29 36.35 24.20 19.49
III Quarter September 43.31 35.97 23.22 15.45
II Quarter June 38.30 32.49 23.57 7.09
I Quarter March 33.45 29.22 25.16 0.06
FY   163.35 134.03 96.15 42.09



DCPH Revenue fourth quarter 2023 Y/Y Growth Comment
Deciphera Pharmaceuticals Inc reported Revenue improvement of 32.86% year on year in the fourth quarter 2023, to $ 48.29 millions, this is lower than Deciphera Pharmaceuticals Inc 's recent average Revenue surge of 1853.08%.

Among companies who have reported fourth quarter 2023 results in the Major Pharmaceutical Preparations industry only one Company has achieved higher year on year Revenue results in the fourth quarter 2023. While Deciphera Pharmaceuticals Inc ' s Revenue rise of 32.86% ranks overall at the positon no. 48 in the fourth quarter 2023.




DCPH Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 32.86 % 50.21 % 24.17 % -
III Quarter September 20.41 % 54.91 % 50.29 % -
II Quarter June 17.88 % 37.84 % 232.44 % -71.64 %
I Quarter March 14.48 % 16.14 % 41833.33 % -99.8 %
FY   21.88 % 39.4 % 128.44 % 68.36 %

Financial Statements
Deciphera Pharmaceuticals Inc 's fourth quarter 2023 Revenue $ 48.29 millions DCPH's Income Statement
Deciphera Pharmaceuticals Inc 's fourth quarter 2022 Revenue $ 36.35 millions Quarterly DCPH's Income Statement
New: More DCPH's historic Revenue Growth >>


DCPH Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 11.51 % 1.06 % 4.22 % 26.15 %
III Quarter September 13.08 % 10.71 % -1.48 % 117.91 %
II Quarter June 14.5 % 11.19 % -6.32 % 11716.67 %
I Quarter March -7.98 % 20.74 % 29.09 % -
FY (Year on Year)   21.88 % 39.4 % 128.44 % 68.36 %




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #4
Overall #48

Revenue Y/Y Growth Statistics
High Average Low
40474.19 % 1853.08 % -100 %
(Mar 31 2021)   (Sep 30 2019)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #4
Overall #48
Revenue Y/Y Growth Statistics
High Average Low
40474.19 % 1853.08 % -100 %
(Mar 31 2021)   (Sep 30 2019)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Deciphera Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
11335.48 % 458.95 % -100 %
(Jun 30 2020)  


DCPH's IV. Quarter Q/Q Revenue Comment
Deciphera Pharmaceuticals Inc achieved in the IV. Quarter 2023 below company average Revenue rise of 11.51% quarter on quarter, to $ 48.29 millions.

Albeit the IV. Quarter 2023 Deciphera Pharmaceuticals Inc 's Revenue sequential growth was below the ordinary of 458.95 %, it was yet good story, as the IV. Quarter improvement, eclipses the 1.06% Revenue surge in the IV. Quarter a year ago

Within Major Pharmaceutical Preparations industry Deciphera Pharmaceuticals Inc achieved highest sequential Revenue growth. While Deciphera Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 75.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #1
Overall #75
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #1
Overall #75
Revenue Q/Q Growth Statistics
High Average Low
11335.48 % 458.95 % -100 %
(Jun 30 2020)  


DCPH's IV. Quarter Q/Q Revenue Comment
Deciphera Pharmaceuticals Inc achieved in the IV. Quarter 2023 below company average Revenue rise of 11.51% quarter on quarter, to $ 48.29 millions.

IV. Quarter 2023 Revenue sequential growth appear to be contradictory, albeit below the ordinary increase of 458.95 %, yet it shows real recovery relative to the 1.06% in the IV. Quarter a year ago.

Within Major Pharmaceutical Preparations industry Deciphera Pharmaceuticals Inc achieved highest sequential Revenue growth. While Deciphera Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 75.


Deciphera Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 163.36 $ 151.41 $ 144.07 $ 138.26 $ 134.04
Y / Y Revenue Growth (TTM) 21.87 % 24.22 % 32.01 % 37.96 % 39.41 %
Year on Year Revenue Growth Overall Ranking # 12 # 34 # 611 # 430 # 77
Seqeuential Revenue Change (TTM) 7.89 % 5.09 % 4.2 % 3.15 % 9.96 %
Seq. Revenue Growth (TTM) Overall Ranking # 96 # 1226 # 1457 # 1973 # 1554




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, Deciphera Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 163 millions, company would post below average annual Revenue growth of 9.96% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the Deciphera Pharmaceuticals Inc 's Revenue growth from the 43.31% growth in Sep 30 2023. Despite that, Deciphera Pharmaceuticals Inc showed the highest Revenue growth, among it's peers in Major Pharmaceutical Preparations industry.

Deciphera Pharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While Total ranking has impoved so far to 12, from total ranking in previous quarter at 34.

Revenue TTM Q/Q Growth Statistics
High Average Low
128.45 %
33.82 %
-106.53 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 0
Overall # 12

Revenue TTM Y/Y Growth Statistics
High Average Low
128.45 %
33.82 %
-106.53 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 5
S&P 500 # 96
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, Deciphera Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 163 millions, company would post below average annual Revenue growth of -106.53% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the Deciphera Pharmaceuticals Inc 's Revenue growth from the 43.31% growth in Sep 30 2023. Despite that, Deciphera Pharmaceuticals Inc showed the highest Revenue growth, among it's peers in Major Pharmaceutical Preparations industry.

Deciphera Pharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While Total ranking has impoved so far to 12, from total ranking in previous quarter at 34.

Revenue TTM Q/Q Growth Statistics
High Average Low
128.45 %
33.82 %
-106.53 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 0
Overall # 12

Revenue TTM Y/Y Growth Statistics
High Average Low
128.45 %
33.82 %
-106.53 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 5
S&P 500 # 96




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DCPH's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for DCPH's Competitors
Revenue Growth for Deciphera Pharmaceuticals Inc 's Suppliers
Revenue Growth for DCPH's Customers

You may also want to know
DCPH's Annual Growth Rates DCPH's Profitability Ratios DCPH's Asset Turnover Ratio DCPH's Dividend Growth
DCPH's Roe DCPH's Valuation Ratios DCPH's Financial Strength Ratios DCPH's Dividend Payout Ratio
DCPH's Roa DCPH's Inventory Turnover Ratio DCPH's Growth Rates DCPH's Dividend Comparisons



Companies with similar Revenue rise for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Tela Bio Inc 53.10%$ 53.102 millions
Theralink Technologies Inc 51.82%$ 51.820 millions
Intra cellular Therapies Inc 50.34%$ 50.336 millions
Adma Biologics Inc 49.43%$ 49.427 millions
Insmed Inc48.27%$ 48.273 millions
Hims and Hers Health Inc 48.15%$ 48.151 millions
Armata Pharmaceuticals Inc 45.39%$ 45.385 millions
G1 Therapeutics Inc 45.10%$ 45.102 millions
Natera inc 43.20%$ 43.200 millions
Shockwave Medical Inc 41.36%$ 41.361 millions
Revance Therapeutics Inc 39.82%$ 39.819 millions
Evolus Inc 39.76%$ 39.759 millions
Ani Pharmaceuticals Inc39.71%$ 39.713 millions
Inspire Medical Systems inc 39.46%$ 39.459 millions
Insulet Corporation37.90%$ 37.896 millions
Foghorn Therapeutics Inc 37.88%$ 37.882 millions
Viemed Healthcare Inc 35.28%$ 35.275 millions
Kiniksa Pharmaceuticals ltd 34.76%$ 34.760 millions
Lantheus Holdings Inc 34.56%$ 34.557 millions
Xeris Biopharma Holdings Inc 33.93%$ 33.931 millions
Deciphera Pharmaceuticals Inc 32.88%$ 32.877 millions
Urogen Pharma Ltd 32.54%$ 32.539 millions
Anaptysbio Inc 32.27%$ 32.271 millions
Twist Bioscience Corporation31.81%$ 31.811 millions
Clearpoint Neuro Inc 31.62%$ 31.620 millions
Amicus Therapeutics inc 31.47%$ 31.466 millions
Corcept Therapeutics Inc31.39%$ 31.390 millions
Harmony Biosciences Holdings inc 31.30%$ 31.303 millions
Alnylam Pharmaceuticals Inc 31.25%$ 31.245 millions
Tarsus Pharmaceuticals Inc 30.76%$ 30.760 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com